Spyre Therapeutics (SYRE) Receivables - Net (2018 - 2024)
Spyre Therapeutics' (SYRE) quarterly Receivables - Net came in at $5.9 million in Q3 2024, little changed on a QoQ basis from $5.9 million in Q2 2024.
Powered by 
Analysis
Spyre Therapeutics (SYRE) Receivables - Net (2018 - 2024) Analysis & Trends
Spyre Therapeutics (SYRE) has 6 years of Receivables - Net data on file, last reported at $5.9 million in Q3 2024.
- Quarterly Receivables - Net changed N/A year-over-year to $5.9 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $5.9 million (changed N/A YoY) and the FY2017 annual result came in at $3.1 million, up 153.33% from the prior year.
- Receivables - Net steadied at $5.9 million in Q3 2024, from $5.9 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $21.5 million in Q1 2021 to a low of $5.9 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Spyre Therapeutics | 7.53 Bn | 7.53 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Mar 31, 2021 | 21.50 Mn |
| Sep 30, 2018 | 2.40 Mn |